Compare CRESY & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | VIR |
|---|---|---|
| Founded | 1936 | 2016 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.2M | 1.5B |
| IPO Year | N/A | 2019 |
| Metric | CRESY | VIR |
|---|---|---|
| Price | $11.10 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 193.8K | ★ 4.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 8.49% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $925.73 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.39 | $4.16 |
| 52 Week High | $14.21 | $10.91 |
| Indicator | CRESY | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 63.90 |
| Support Level | $11.07 | $4.95 |
| Resistance Level | $12.34 | $10.91 |
| Average True Range (ATR) | 0.46 | 0.69 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 34.29 | 69.49 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.